FranceFrance

Servier pays for rights for microRNA candidates from MiRagen

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and commercialisation of two of the most promising candidates to treat cardiovascular disease, miR-208 and miR-15/195, as well as one yet-to-be-determined discovery target. In exchange for commercialisation rights outside the U.S. and Japan, miRagen gets US$45 million in an upfront payment, research support and near-term milestones, up to US$352 million in total milestones and double-digit royalties on approved products. It's a "transformational deal" for the fledgling MiRagen, a company that has raised US$18 million in venture capital since its 2007 founding, said CEO William Marshall. The deal is also welcome news to Atlas Venture and Boulder Ventures, which helped launch miRagen with an US$8 million Series A back in 2008. "It's always been a question of 'How do we get (the large-scale trials)?'" Marshall said. "Now we've got a clear path to that." Inhibiting microRNA-208 could increase resistance to cardiac stress, while the inhibition of miR-15/195 not only reduces the amount of cells that die after a heart attack, but also shows promise in helping the regeneration of cells.


FranceFrance

28.03.2012

Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...

FranceFrance

14.03.2012

Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...

FranceFrance

13.03.2012

Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...

FranceFrance

06.03.2012

Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...

FranceFrance

05.03.2012

Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...

FranceFrance

27.02.2012

Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...

FranceFrance

07.02.2012

Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...

FranceFrance

06.02.2012

Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...

FranceFrance

02.02.2012

Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...

FranceFrance

12.01.2012

Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-france/article/servier-pays-for-rights-for-microrna-candidates-from-miragen.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.30 CHF6.45%
  • PAION3.17 EUR3.93%
  • SANTHERA90.75 CHF3.07%

FLOP

  • WILEX2.36 EUR-12.27%
  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.23 CHF-4.17%

TOP

  • CO.DON3.27 EUR30.8%
  • PAION3.17 EUR27.8%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • MEDIGENE3.82 EUR-17.8%
  • ADDEX3.30 CHF-17.5%
  • EVOTEC3.10 EUR-15.5%

TOP

  • SANTHERA90.75 CHF2124.3%
  • CO.DON3.27 EUR280.2%
  • PAION3.17 EUR213.9%

FLOP

  • CYTOS0.23 CHF-94.3%
  • THERAMETRICS0.08 CHF-42.9%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 21.09.2014


Current issue

All issues

Product of the week

Products